Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Tagrisso (osimertinib)
pCPA File Number:
21016
Negotiation Status:
Concluded with an LOI
Indication(s):
Non-Squamous Non-Small Cell Lung Cancer
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CADTH Project Number:
pCODR 10076
pCPA Engagement Letter Issued:
2017-09-29
Negotiation Process Concluded:
2018-07-30